Cargando…
Tumour Heterogeneity: The Key Advantages of Single-Cell Analysis
Tumour heterogeneity refers to the fact that different tumour cells can show distinct morphological and phenotypic profiles, including cellular morphology, gene expression, metabolism, motility, proliferation and metastatic potential. This phenomenon occurs both between tumours (inter-tumour heterog...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5187942/ https://www.ncbi.nlm.nih.gov/pubmed/27999407 http://dx.doi.org/10.3390/ijms17122142 |
_version_ | 1782486932441268224 |
---|---|
author | Tellez-Gabriel, Marta Ory, Benjamin Lamoureux, Francois Heymann, Marie-Francoise Heymann, Dominique |
author_facet | Tellez-Gabriel, Marta Ory, Benjamin Lamoureux, Francois Heymann, Marie-Francoise Heymann, Dominique |
author_sort | Tellez-Gabriel, Marta |
collection | PubMed |
description | Tumour heterogeneity refers to the fact that different tumour cells can show distinct morphological and phenotypic profiles, including cellular morphology, gene expression, metabolism, motility, proliferation and metastatic potential. This phenomenon occurs both between tumours (inter-tumour heterogeneity) and within tumours (intra-tumour heterogeneity), and it is caused by genetic and non-genetic factors. The heterogeneity of cancer cells introduces significant challenges in using molecular prognostic markers as well as for classifying patients that might benefit from specific therapies. Thus, research efforts for characterizing heterogeneity would be useful for a better understanding of the causes and progression of disease. It has been suggested that the study of heterogeneity within Circulating Tumour Cells (CTCs) could also reflect the full spectrum of mutations of the disease more accurately than a single biopsy of a primary or metastatic tumour. In previous years, many high throughput methodologies have raised for the study of heterogeneity at different levels (i.e., RNA, DNA, protein and epigenetic events). The aim of the current review is to stress clinical implications of tumour heterogeneity, as well as current available methodologies for their study, paying specific attention to those able to assess heterogeneity at the single cell level. |
format | Online Article Text |
id | pubmed-5187942 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-51879422016-12-30 Tumour Heterogeneity: The Key Advantages of Single-Cell Analysis Tellez-Gabriel, Marta Ory, Benjamin Lamoureux, Francois Heymann, Marie-Francoise Heymann, Dominique Int J Mol Sci Review Tumour heterogeneity refers to the fact that different tumour cells can show distinct morphological and phenotypic profiles, including cellular morphology, gene expression, metabolism, motility, proliferation and metastatic potential. This phenomenon occurs both between tumours (inter-tumour heterogeneity) and within tumours (intra-tumour heterogeneity), and it is caused by genetic and non-genetic factors. The heterogeneity of cancer cells introduces significant challenges in using molecular prognostic markers as well as for classifying patients that might benefit from specific therapies. Thus, research efforts for characterizing heterogeneity would be useful for a better understanding of the causes and progression of disease. It has been suggested that the study of heterogeneity within Circulating Tumour Cells (CTCs) could also reflect the full spectrum of mutations of the disease more accurately than a single biopsy of a primary or metastatic tumour. In previous years, many high throughput methodologies have raised for the study of heterogeneity at different levels (i.e., RNA, DNA, protein and epigenetic events). The aim of the current review is to stress clinical implications of tumour heterogeneity, as well as current available methodologies for their study, paying specific attention to those able to assess heterogeneity at the single cell level. MDPI 2016-12-20 /pmc/articles/PMC5187942/ /pubmed/27999407 http://dx.doi.org/10.3390/ijms17122142 Text en © 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Tellez-Gabriel, Marta Ory, Benjamin Lamoureux, Francois Heymann, Marie-Francoise Heymann, Dominique Tumour Heterogeneity: The Key Advantages of Single-Cell Analysis |
title | Tumour Heterogeneity: The Key Advantages of Single-Cell Analysis |
title_full | Tumour Heterogeneity: The Key Advantages of Single-Cell Analysis |
title_fullStr | Tumour Heterogeneity: The Key Advantages of Single-Cell Analysis |
title_full_unstemmed | Tumour Heterogeneity: The Key Advantages of Single-Cell Analysis |
title_short | Tumour Heterogeneity: The Key Advantages of Single-Cell Analysis |
title_sort | tumour heterogeneity: the key advantages of single-cell analysis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5187942/ https://www.ncbi.nlm.nih.gov/pubmed/27999407 http://dx.doi.org/10.3390/ijms17122142 |
work_keys_str_mv | AT tellezgabrielmarta tumourheterogeneitythekeyadvantagesofsinglecellanalysis AT orybenjamin tumourheterogeneitythekeyadvantagesofsinglecellanalysis AT lamoureuxfrancois tumourheterogeneitythekeyadvantagesofsinglecellanalysis AT heymannmariefrancoise tumourheterogeneitythekeyadvantagesofsinglecellanalysis AT heymanndominique tumourheterogeneitythekeyadvantagesofsinglecellanalysis |